Jane Street Group LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)

Jane Street Group LLC bought a new stake in Upstream Bio, Inc. (NASDAQ:UPB) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 45,549 shares of the company’s stock, valued at approximately $749,000. Jane Street Group LLC owned 0.08% of Upstream Bio at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Samsara BioCapital LLC purchased a new position in shares of Upstream Bio in the fourth quarter valued at $36,450,000. Soros Fund Management LLC bought a new position in Upstream Bio during the 4th quarter valued at $762,000. TCG Crossover Management LLC bought a new position in Upstream Bio during the 4th quarter valued at $44,856,000. Nantahala Capital Management LLC bought a new position in Upstream Bio during the 4th quarter valued at $9,864,000. Finally, Northern Trust Corp bought a new position in Upstream Bio during the 4th quarter valued at $2,363,000.

Upstream Bio Trading Down 1.6%

NASDAQ UPB opened at $9.16 on Monday. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46. The company’s fifty day moving average price is $8.04 and its two-hundred day moving average price is $12.26.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.71 million. Analysts predict that Upstream Bio, Inc. will post -4.3 EPS for the current year.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.